1)Alibert JLM:Descriptions des maladies de la peau: observées a l’Hôpital Saint-Louis, et exposition des meilleures méthodes suivies pour leur traitement (in French), Barrois l’ainé, Paris,p286,1806
2)Sézary A, Bouvrain Y:Erythrodermie avec présence de cellules monstruenses clans le derme et le sang circulant. Bull Soc Fr Dermatol Syph 45:254-260,1938
3)Ralfkiaer E, Willemze R, Whittaker SJ:Sezary syndrome. In: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th ed (Swerdlow SH, Campo E, Harris NL, et al eds), IARC Press, Lyon,p299,2008
4)濱田利久,岩月啓氏:皮膚リンパ腫 全国症例数調査の結果 2011,第28回日本皮膚悪性腫瘍学会パネルディスカッション,2012
5)Willemze R, Jaffe ES, Burg G, et al:WHO-EORTC classification for cutaneous lymphomas. Blood 105:3768-3785,2005
6)Kim EJ, Hess S, Richardson SK, et al:Immunopathogenesis and therapy of cutaneous T cell lymphoma. J Clin Invest 115:798-812,2005
7)Olsen E, Vonderheid E, Pimpinelli N, et al:Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 110:1713-1722,2007
8)Guitart J:Beyond clonal detection: defining the T-cell clone. Arch Dermatol 141:1159,2005
9)Harmon CB, Witzig TE, Katzmann JA, et al:Detection of circulating T cells with CD4+CD7- immunophenotype in patients with benign and malignant lymphoproliferative dermatoses. J Am Acad Dermatol 35:404-410,1996
10)Bernengo MG, Novelli M, Quaglino P, et al:The relevance of the CD4+ CD26- subset in the identification of circulating Sézary cells. Br J Dermatol 144:125-135,2001
11)Campbell JJ, Clark RA, Watanabe R, et al:Sezary syndrome and mycosis fungoides arise from distinct T-cell subsets: a biologic rationale for their distinct clinical behaviors. Blood 116:767-771,2010